(Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, ...

Gig roles are emerging in India's corporate sector, with IT, pharmaceuticals, and energy firms hiring senior executives on ...

Good morning, and welcome to the Altamira Therapeutics First Half 2024 and Business Update Conference Call. On today's call are Thomas Meyer, Altamira's Founder, Chairman and Chief Executive Officer; ...

Silexion Therapeutics sees surge in trading volume after revealing new findings from a Phase 2 trial of LODER in pancreatic ...

Altamira’s Senior Management will hold an investor call today, Tuesday, September 24, 2024, at 8:30 a.m. EDT its business update and first half 2024 results. Founder, Chairman, and CEO Thomas Meyer ...

HOOKIPA is very pleased to present a comprehensive preclinical proof-of-concept dataset related to HB-700, for the potential treatment of KRAS mutated cancers. KRAS mutations are most frequently found ...

New research from the University of Dundee shows potential breakthrough for hard to treat cancers. Experts from the ...

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide.

Molecule sends 13 of the 17 most common forms of this cancer-related protein to the cell’s garbage-disposal system ...

Experts have developed a breakthrough small-molecule drug, a 'protein degrader'. This molecule, called ACBI3, could potentially lead to new therapies independent of KRAS mutation type, improving ...

Experts from the University of of Dundee's Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim scientists, have developed a breakthrough small-molecule drug, a "protein ...

A novel CAR T-cell therapy, GCC19CART, has demonstrated activity in patients with heavily pretreated, metastatic colorectal cancer.